[HTML][HTML] Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) …
Abstract Abstract 114 Background: Romidepsin is a potent HDAC inhibitor approved by the
FDA for patients (pts) with cutaneous T-cell lymphoma who have received at least 1 prior …
FDA for patients (pts) with cutaneous T-cell lymphoma who have received at least 1 prior …
[引用][C] Final Results From a Pivotal, Multicenter, International, Open Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma …
B Coiffier, B Pro, HM Prince, FM Foss, L Sokol… - BLOOD, 2010 - pure.pmu.ac.at
Final Results From a Pivotal, Multicenter, International, Open Label, Phase 2 Study of
Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior …
Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior …
Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) …
B Coiffier, B Pro, HM Prince, FM Foss, L Sokol… - 2010 - ashpublications.org
Abstract Abstract 114 Background: Romidepsin is a potent HDAC inhibitor approved by the
FDA for patients (pts) with cutaneous T-cell lymphoma who have received at least 1 prior …
FDA for patients (pts) with cutaneous T-cell lymphoma who have received at least 1 prior …
[引用][C] Final Results From a Pivotal, Multicenter, International, Open Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma …
B Coiffier, B Pro, HM Prince, FM Foss, L Sokol… - BLOOD, 2010 - pure.pmu.ac.at
Final Results From a Pivotal, Multicenter, International, Open Label, Phase 2 Study of
Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior …
Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior …